Investors pile on Stanford spinout promising new ways to attack cancer, autoimmune diseases

This post was originally published on this site

[unable to retrieve full-text content]In less than 2 years, this @Stanford spinout has attracted nearly $200M as it targets inflammation-signaling cytokines. Find out why.